Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis
Supportive Care in Cancer · 2026-06 · 34 (6)
DOI: 10.1007/s00520-026-10745-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 14.05.2026. Verfasst von Majd A Abualrob und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Hamad General Hospital, Doha, Qatar. majdaiabualrob72@gmail.com. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Neurotoxicity Syndromes, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) have transformed melanoma treatment, yet comparative real-world data characterizing ICI-associated neurologic adverse events against the well-established neurotoxicity profile of conventional chemotherapy remain limited. We sought to contextualize the neurologic risk landscape of ICIs relative to chemotherapy as a historical comparator, to inform treatment-specific supportive care and surveillance strategies.
Methods
We performed a propensity score–matched analysis using the TriNetX Global Collaborative Network, encompassing 162 healthcare organizations. Adult patients with melanoma receiving chemotherapy (dacarbazine, paclitaxel, carboplatin, or temozolomide; n = 9787) or ICI therapy (pembrolizumab, nivolumab, or ipilimumab; n = 14,627) from January 2014 through November 2025 were identified. After 1:1 nearest-neighbor matching on 52 baseline covariates, 6887 pairs were analyzed over 1–1095 days post-index therapy. Primary outcomes were peripheral neuropathy, encephalopathy, and laboratory-anchored myositis (ICD-10 myositis codes with creatine kinase ≥ 500 U/L). Fractures served as a negative control. A pre-specified conservative sensitivity analysis excluded bidirectional treatment switching, restricted the ICI cohort to anti-PD-1 predominant exposure, tightened outcome definitions, and extended follow-up to 5 years.
Results
Among 13,774 matched patients (mean age 67.1 years; 48.5% male), peripheral neuropathy occurred in 7.2% of chemotherapy-treated versus 3.2% of ICI-treated patients (HR 2.47; 95% CI 2.10–2.92). Encephalopathy occurred in 1.0% versus 1.4% (HR 0.70; 95% CI 0.51–0.96). Laboratory-confirmed myositis occurred in 1.0% versus 2.1% (HR 0.47; 95% CI 0.35–0.64). No cases of Guillain–Barré syndrome or CNS vasculitis were detected. The negative control showed no significant difference ( P = .20). In the conservative sensitivity analysis (6640 matched pairs; 5-year follow-up), the peripheral neuropathy association was substantially strengthened (HR 5.45; 95% CI 4.16–7.15) and the laboratory-anchored myositis association was essentially unchanged (HR 0.46; 95% CI 0.33–0.64), while the encephalopathy association attenuated to null (HR 1.03; 95% CI 0.79–1.34).
Conclusions
Chemotherapy carries a substantially higher peripheral neuropathy risk, while ICI therapy confers elevated laboratory-confirmed myositis risk. These robust findings support treatment-specific neurologic surveillance and supportive care strategies in melanoma management, particularly neuropathy monitoring during chemotherapy and neuromuscular/CK surveillance during ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Institute, Hamad General Hospital, Doha, Qatar. majdaiabualrob72@gmail.com.
- Neuroscience Institute, Hamad General Hospital, Doha, Qatar.
- Internal Medicine, Hamad General Hospital, Doha, Qatar.
- Arab American University, Jenin, Palestine.
- Palestinian Ministry of Health, Ramallah, Palestine.
- Neurology Department, Creighton University, Omaha, NE, USA.
Förderung
- Hamad Medical Corporation
Zitieren
APA
Abualrob, M. A., Alshehab, S., Awad, Y., Toma, R., Azzam, T., Abdellatif, R., Al-Salahat, A., & Hamid, S. (2026). Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis. Supportive Care in Cancer, 34(6). https://doi.org/10.1007/s00520-026-10745-4
Vancouver
Abualrob MA, Alshehab S, Awad Y, Toma R, Azzam T, Abdellatif R, et al. Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis. Supportive Care in Cancer. 2026;34(6). doi:10.1007/s00520-026-10745-4
BibTeX
@article{Abualrob2026,
author = {Abualrob, Majd A and Alshehab, Sami and Awad, Yousef and Toma, Ranim and Azzam, Tarneem and Abdellatif, Rand and Al-Salahat, Ali and Hamid, Shahd},
title = {Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {6},
doi = {10.1007/s00520-026-10745-4}
}
EUVIMED